Vanda Pharmaceuticals | VNDA - Gross Profit On Sales


Vanda Pharmaceuticals reported $50.6M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 12.61B 225M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Eli Lilly USD 15.92B 1.33B Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 297.47M 75.53M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 256.46M 38.78M Mar/2026
J&J USD 17.24B 642M Mar/2026
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
Ligand Pharmaceuticals USD 48.45M 8.22M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD -566M 792M Mar/2026
Novartis USD 10.82B 694M Sep/2025
Pfizer USD 11.04B 1.24B Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 1.31B Dec/2025
Takeda JPY 688.84B 101.71B Mar/2026
Teva Pharmaceutical Industries USD 2.11B 547M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Veracyte USD 101.16M 814K Mar/2026